Outi Varpuluoma

Oulu, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Clinical description and management of two terbinafine-resistant cases of tinea caused by Trichophyton indotineae from Finland.

Clinical description and management of two terbinafine-resistant cases of tinea caused by Trichophyton indotineae from Finland.

Journal: Skin health and disease

Published: February 07, 2026

Genes associated with immune response are upregulated in clinically healthy skin of patients with gliptin-associated bullous pemphigoid.

Genes associated with immune response are upregulated in clinically healthy skin of patients with gliptin-associated bullous pemphigoid.

Journal: The Journal of investigative dermatology

Published: September 04, 2025

Widespread Rash with Localized Sparing: A Quiz.

Widespread Rash with Localized Sparing: A Quiz.

Journal: Acta dermato-venereologica

Published: January 31, 2025

Treatment of bullous pemphigoid with methotrexate is associated with a decreased mortality risk.

Treatment of bullous pemphigoid with methotrexate is associated with a decreased mortality risk.

Journal: The British journal of dermatology

Published: January 18, 2025

Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid.

Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid.

Journal: Acta dermato-venereologica

Published: April 23, 2024

Epidemiology and Comorbidities of Mucous Membrane Pemphigoid: A National Cohort Study.

Epidemiology and Comorbidities of Mucous Membrane Pemphigoid: A National Cohort Study.

Journal: The Journal of investigative dermatology

Published: November 17, 2023

Accurate diagnosis of bullous pemphigoid requires multiple health care visits.

Accurate diagnosis of bullous pemphigoid requires multiple health care visits.

Journal: Frontiers in immunology

Published: August 22, 2023

Solid and hematological malignancies in patients with bullous pemphigoid: A national cohort study.

Solid and hematological malignancies in patients with bullous pemphigoid: A national cohort study.

Journal: Journal of the American Academy of Dermatology

Published: August 18, 2023

Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.

Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.

Journal: Frontiers in immunology

Published: May 12, 2022

Ulcerative Tuberculosis in a Patient Treated with Adalimumab.

Ulcerative Tuberculosis in a Patient Treated with Adalimumab.

Journal: Acta dermato-venereologica

Published: March 31, 2022

Dipeptidyl Peptidase 4 Inhibitor‒Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin.

Dipeptidyl Peptidase 4 Inhibitor‒Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin.

Journal: The Journal of investigative dermatology

Published: February 28, 2022

GLP-1 Analogs and SGLT2 Inhibitors Do Not Increase Risk of Bullous Pemphigoid.

GLP-1 Analogs and SGLT2 Inhibitors Do Not Increase Risk of Bullous Pemphigoid.

Journal: The Journal of investigative dermatology

Published: February 17, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026